Trade Summary

5 days ago, Tzianabos Arthur, serving as Interim Exec Chair at Stoke Therapeutics, Inc. (STOK), sold 4,355 shares at $40.00 per share, for a total transaction value of $174,214.00. Following this transaction, Tzianabos Arthur now holds 31,339 shares of STOK.

This sale represents a 12.00% decrease in Tzianabos Arthur's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 10, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 12, 2026, 2 days after the trade was made.

Stoke Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.